Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

66.60 +0.71 (+1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,644,395
Open 65.70
Bid (Size) 65.80 (1)
Ask (Size) 67.56 (1)
Prev. Close 65.89
Today's Range 65.60 - 66.81
52wk Range 65.35 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
Via Benzinga

Performance

YTD
-32.08%
-32.08%
1 Month
-2.29%
-2.29%
3 Month
-17.24%
-17.24%
6 Month
-18.88%
-18.88%
1 Year
-16.32%
-16.32%

More News

Read More
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
Via Benzinga
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
How Is The Market Feeling About Biomarin Pharmaceutical?
Via Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Via Benzinga
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
3 Oversold Stocks with Big RSI Rebound Potential
Via MarketBeat
Topics Economy
Exposures Interest Rates
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Via Chartmill
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
Via Chartmill
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Via Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Via Investor's Business Daily
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.